Fractal formulations
AssigneeNANOGYRE Sprl
InventorJallal Messadek
Life of this patent
Estimating the term…
Abstract
Glycine betaine based liquid crystal comprising in dry matter at least: 80 to 99.5% by weight of glycine betaine, and 0.5 to 20% by weight of a non-ionic water soluble tensioactive system having a HLB value equal to 12 or more than 12, whereby the weight ratio glycine betaine/non-ionic water soluble tensioactive system is greater than 10, said glycine betaine and said non-ionic water soluble tensioactive being solubilized in water for forming the glycine betaine based liquid crystal.
Claims39
A glycine betaine based liquid crystal comprising in dry matter at least:
- 80 to 99.5% by weight of glycine betaine of formula (CH3)3N+CH2COO−, CAS number:
- 107-43-7, and
- 0.5 to 20% by weight of a non-ionic water soluble tensioactive system selected from the group consisting of non-ionic water soluble tensioactive agents having a HLB value equal to 12 or more than 12 and mixtures of non-ionic water soluble tensioactive agents having each a HLB value equal to 12 or more than 12,
- whereby the weight ratio glycine betaine/non-ionic water soluble tensioactive system is greater than 10:1,
- said glycine betaine and said non-ionic water soluble tensioactive being solubilized in water with a weight ratio glycine betaine/water comprised between 1:3 to 3:1 for forming the glycine betaine based liquid crystal.
A composition for administering to a mammal a therapeutic entity, said composition comprising:
- glycine betaine based liquid crystals comprising in dry matter at least:
- 80 to 99.5% by weight of glycine betaine of formula (CH3)3N+CH2COO−, CAS number:
- 107-43-7,
- 0.5 to 20% by weight of a non-ionic water soluble tensioactive system selected from the group consisting of non-ionic water soluble tensioactive agents having a HLB value equal to 12 or more than 12 and mixtures of non-ionic water soluble tensioactive agents having each a HLB value equal to 12 or more than 12, and
- a quantity of the hydrophobic entity,
- whereby the weight ratio glycine betaine/non-ionic water soluble tensioactive system is greater than 10:1, and whereby the weight ratio glycine betaine/hydrophobic entity is equal to or greater than 5:1,
- said glycine betaine and said non-ionic water soluble tensioactive being solubilized in water with a weight ratio glycine betaine/water comprised between 1:3 to 3:1 for forming the glycine betaine based liquid crystal.
The composition of 13, in which the glycine betaine based liquid crystals have a particle size of less than 350 nanometers.
The composition of 13, in which the glycine betaine based liquid crystals have a particle size of less than 100 nanometers.
The composition of 13, in which the glycine betaine based liquid crystals have a particle size of less than 20 nanometers.
The composition of 13, in which the weight ratio glycine betaine/non-ionic water soluble tensioactive system of the glycine betaine based liquid crystals is comprised between 20:1 and 50:1.
The composition of 13, in which the non-ionic water soluble tensioactive system of the glycine betaine based liquid crystals is selected from the group consisting of non-ionic water soluble tensioactive agents having a HLB value equal to or more than 14 and mixtures of non-ionic water soluble tensioactive agents having each a HLB value equal to 13 or more than 13.
The composition of 13, in which the non-ionic water soluble tensioactive system of the glycine betaine based liquid crystals is selected from the group consisting of Tween 20 (E432-HLB 15), Tween 80 (E433-HLB 15), Tween 40 (E434-HLB 15.6), Tween 60 (E435-HLB 14.9), Tween 65 (E436-HLB 10.5), Quillaja Saponaria Molina (E999), as well as their mixtures.
A process for the preparation of a glycine betaine based liquid crystal comprising in dry matter at least:
- 80 to 99.5% by weight of glycine betaine of formula (CH3)3N+CH2COO−, CAS number:
- 107-43-7, and
- 0.5 to 20% by weight of a non-ionic water soluble tensioactive system selected from the group consisting of non-ionic water soluble tensioactive agents having a HLB value equal to or more than 12 and mixtures of non-ionic water soluble tensioactive agents having each a HLB value equal to 12 or more than 12,
- whereby the weight ratio glycine betaine/non-ionic water soluble tensioactive system is greater than 10:1.
- said process comprising at least the following steps:
- a preparation step of an aqueous medium comprising water, the glycine betaine and the tensioactive system, whereby in dry matter the aqueous medium comprises at least:
- 80 to 99.5% by weight of glycine betaine of formula (CH3)3N+CH2COO−, CAS number:
- 107-43-7, and
- 0.5 to 20% by weight of a non-ionic water soluble tensioactive system selected from the group consisting of non-ionic water soluble tensioactive agents having a HLB value equal to 12 or more than 12 and mixtures of non-ionic water soluble tensioactive agents having each a HLB value equal to 12 or more than 12,
- whereby the weight ratio glycine betaine/non-ionic water soluble tensioactive system is greater than 10:1,
- said glycine betaine and said non-ionic water soluble tensioactive being solubilized in water with a weight ratio glycine betaine/water comprised between 1:3 to 3:1, and
- a mixing step of the aqueous medium for forming the glycine betaine based liquid crystal.
A method of treatment of a mammal selected from the group consisting of:
- (a) mammals suffering at least one trouble from a disease, and
- (b) mammals at risk of suffering at least one trouble from a disease, by administering to said mammal at least a dose of a therapeutic entity selected from the group consisting of nutrients, pharmaceutical substances and mixtures thereof,
- in which the therapeutic entity to be administered is in the form of a composition comprising
- glycine betaine based liquid crystals comprising each in dry matter at least:
- 80 to 99.5% by weight of glycine betaine of formula (CH3)3N+CH2COO−, CAS number:
- 107-43-7,
- 0.5 to 20% by weight of a non-ionic water soluble tensioactive system selected from the group consisting of non-ionic water soluble tensioactive agents having a HLB value equal to 12 or more than 12 and mixtures of non-ionic water soluble tensioactive agents having each a HLB value equal to 12 or more than 12, and
- a quantity of the hydrophobic entity,
- whereby the weight ratio glycine betaine/non-ionic water soluble tensioactive system is greater than 10:1, and whereby the weight ratio glycine betaine/therapeutic entity is equal to or greater than 5:1,
Dependencies are inferred from the claim text.